Fractyl Health (GUTS) Other Non-Current Liabilities (2023 - 2026)
Fractyl Health's (GUTS) quarterly Other Non-Current Liabilities came in at $569000.0 in Q1 2026, down 38.15% YoY from $920000.0 in Q1 2025, and down 14.18% on a QoQ basis from $663000.0 in Q4 2025.
Fractyl Health (GUTS) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Other Non-Current Liabilities data on file, last reported at $569000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 38.15% year-over-year to $569000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $569000.0 (down 38.15% YoY) and the FY2025 annual result came in at $663000.0, down 33.57% from the prior year.
- Other Non-Current Liabilities slipped to $569000.0 in Q1 2026, from $663000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $2.6 million in Q3 2023 to a low of $330000.0 in Q1 2024.
- A 4-year average of $970700.0 and a median of $879000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 58.77% — and 2025, when it jumped 178.79%.
- Tracing GUTS's Other Non-Current Liabilities over 4 years: stood at $2.6 million in 2023, then plunged by 61.62% to $998000.0 in 2024, then plunged by 33.57% to $663000.0 in 2025, then retreated by 14.18% to $569000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $569000.0 (Q1 2026), $663000.0 (Q4 2025), and $753000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 510,000.00 |
| Mar 31, 2026 | 569,000.00 |
| Dec 31, 2025 | 663,000.00 |
| Sep 30, 2025 | 753,000.00 |
| Jun 30, 2025 | 838,000.00 |
| Mar 31, 2025 | 920,000.00 |
| Dec 31, 2024 | 998,000.00 |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 964,000.00 |
| Mar 31, 2024 | 330,000.00 |
| Sep 30, 2023 | 2.60 Mn |